Tag: fundraising

Company News: Oberland Capital Raises $425 Million Healthcare Royalty and Credit Opportunities Fund


– Significantly Exceeds Target –

Oberland Capital, an investment firm focused on the global healthcare industry, announced today the closing of its inaugural royalty and credit opportunities fund, Oberland Capital Healthcare, with $425 million in capital commitments.

Oberland Capital provides healthcare companies, institutions and inventors customized financing solutions with an emphasis on the biopharmaceutical, medical device and diagnostic sectors.  The fund targets investments ranging from $15 million to $100 million and has the ability to execute substantially larger transactions.

“We are grateful for the support shown by our limited partners in helping us to significantly surpass the $350 million target size for our first fund.  The strong response from investors is a testament to the quality and experience of our investment team and the demand for non-correlated investment strategies.  We look forward to building a diversified portfolio of attractive healthcare investments,” said Andrew Rubinstein, Managing Partner.

The development and commercialization of breakthrough medical technologies is highly capital intensive, creating a large market opportunity for Oberland Capital Healthcare.  “Our flexible, long-term financing solutions provide an attractive source of capital to healthcare companies, institutions and inventors,” added Jean-Pierre Naegeli, Managing Partner.  “We are excited to work with our transaction partners worldwide to enable them to meet their strategic and financial objectives.”

Investors in Oberland Capital Healthcare include public and corporate pension plans, financial institutions, foundations and endowments located throughout the United States and Europe.

Company News: Affectis Pharmaceuticals Raises €3.3M in Financing and Names Alex Martin Chief Executive Officer

Affectis Pharmaceuticals AG today announced it has raised €3.3M in the first tranche of a Series D financing. Existing investors LSP, Aescap Venture, KfW, Bayernkapital and EMBL Ventures were participating in the round. Moreover, the company announced the appointment of Alex Martin as Chief Executive Officer. Mr. Martin had previously served on the Supervisory Board of Affectis and joined the company fulltime as CFO in August of 2009. He succeeds founding CEO Herbert Stadler, who is retiring.

Mr. Martin brings over 20 years experience in the pharmaceutical industry, including roles at Novartis, where he was Vice President, Global Business Development & Licensing, and SmithKline Beecham where he held positions of increasing responsibility in sales, marketing, and business development. Immediately prior to Affectis Mr. Martin served as COO of Intercept Pharmaceuticals based in New York.

The full announcement is available at Affectis’  website.